Low titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccination.
BACKGROUND
Resurgence or outbreak of measles recently occurred in both developed and developing countries despite long-standing widespread use of measles vaccine. Measles incidence in China has increased since 2002, particularly in infants and in persons >or= 15 years of age. It is speculated that infants may acquire fewer measles IgG from their mothers, resulting in the reduced duration of protection during their early months of life. This study aimed to clarify the reason of increased susceptibility to measles in young infants in China. Measles IgG in 24 measles infants <or= 9 months of age and their vaccinated mothers was quantitatively measured. The mean measles neutralizing titer in the vaccinated mothers and in 13 age-match women with the histories of clinical measles were compared.


RESULTS
All the mothers were confirmed to be vaccinated successfully by the presence of measles IgG. Six vaccinated mothers were positive for measles IgM and had high concentrations of measles IgG and the neutralizing antibody, indicating underwent natural boosting. The mean measles neutralizing titer in 18 vaccinated mothers without natural boosting were significantly lower than that in 13 age-match women with the histories of clinical measles (1:37 vs 1:182, P < 0.05).


CONCLUSIONS
Our results suggest that infants born to mothers who acquired immunity to measles by vaccination may get a relatively small amount of measles antibody, resulting in loss of the immunity to measles before the vaccination age. Measures to improve the immunity in young infants not eligible for measles vaccination would be critical to interrupt the measles transmission in China.
Zhao
Hong
H
Department of Infectious Diseases, Nanjing Second Hospital, Nanjing, China.
Lu
Pei-Shan
PS
Hu
Yali
Y
Wu
Qiaozhen
Q
Yao
Wenhu
W
Zhou
Yi-Hua
YH
D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D002681:China; D005260:Female; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D008297:Male; D008457:Measles / Q000453:epidemiology* / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000276:immunology*; D009035:Mothers
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine
J Infect Dis. 2003 May 15;187 Suppl 1:S252-7
12721922
Vaccine. 2007 Apr 20;25(16):3105-10
17306425
Clin Diagn Lab Immunol. 2003 Sep;10(5):751-6
12965899
J Med Virol. 1993 Sep;41(1):44-8
8228936
Am J Hyg. 1961 Nov;74:293-303
13917381
Clin Diagn Lab Immunol. 1999 Mar;6(2):178-80
10066650
Pediatrics. 1999 Nov;104(5):e59
10545585
Med Microbiol Immunol. 2007 Sep;196(3):151-5
17308917
Epidemiol Infect. 2005 Feb;133(1):99-105
15724716
BMJ. 2008 Jul 24;337:a661
18653640
Viral Immunol. 1997;10(3):165-73
9344339
JAMA. 1998 Aug 12;280(6):527-32
9707142
Pediatr Infect Dis J. 2007 Jun;26(6):513-8
17529869
Vaccine. 2007 Aug 21;25(34):6296-304
17629601
J Clin Microbiol. 2006 Aug;44(8):2733-8
16891485